Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Kim

Showing results (31-40 of 226) with videos related to

Pageof 23
Sort By:
Current Opinion in Lipidology|March 10, 2016
Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosisAze Wilson, Cheynne McLean, Richard B Kim
Journal of Clinical Pharmacology|July 8, 2016
Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Cheynne McLean, Aze Wilson, Richard B Kim
Annals of Internal Medicine|March 15, 2021
Rosuvastatin Myotoxicity After Starting Canagliflozin TreatmentEugene Brailovski, Richard B Kim, David Juurlink
Journal of Patient Experience|February 5, 2024
Patients' Experiences of a Precision Medicine ClinicDavid Barrett, Jovana Sibalija, Richard B Kim
Clinical Pharmacology and Therapeutics|May 7, 2003
"Inactive" excipients such as Cremophor can affect in vivo drug dispositionCristoph Wandel, Richard B Kim, C Michael Stein
Molecular Pharmaceutics|June 30, 2009
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphismsHenriette E Meyer zu Schwabedissen, Richard B Kim
Cold Spring Harbor Perspectives in Medicine|May 31, 2018
The Role of Next-Generation Sequencing in Pharmacogenetics and PharmacogenomicsUte I Schwarz, Markus Gulilat, Richard B Kim
Digestive Diseases and Sciences|July 27, 2021
A Comparative Analysis of Drug Therapy, Disease Phenotype, and Health Care Outcomes for Men and Women with Inflammatory Bowel DiseaseEmily M Heath, Richard B Kim, Aze Wilson
Inflammatory Bowel Diseases|March 17, 2017
CYP3A4 Activity is Markedly Lower in Patients with Crohn's DiseaseAze Wilson, Rommel G Tirona, Richard B Kim
Cancer Chemotherapy and Pharmacology|November 11, 2022
Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotypeSamantha Medwid, Theodore J Wigle, Richard B Kim
Pageof 23

Showing results (31-40 of 226) with videos related to

Sort By:
Pageof 23
Current Opinion in Lipidology|March 10, 2016
Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosisAze Wilson, Cheynne McLean, Richard B Kim
Journal of Clinical Pharmacology|July 8, 2016
Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Cheynne McLean, Aze Wilson, Richard B Kim
Annals of Internal Medicine|March 15, 2021
Rosuvastatin Myotoxicity After Starting Canagliflozin TreatmentEugene Brailovski, Richard B Kim, David Juurlink
Journal of Patient Experience|February 5, 2024
Patients' Experiences of a Precision Medicine ClinicDavid Barrett, Jovana Sibalija, Richard B Kim
Clinical Pharmacology and Therapeutics|May 7, 2003
"Inactive" excipients such as Cremophor can affect in vivo drug dispositionCristoph Wandel, Richard B Kim, C Michael Stein
Molecular Pharmaceutics|June 30, 2009
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphismsHenriette E Meyer zu Schwabedissen, Richard B Kim
Cold Spring Harbor Perspectives in Medicine|May 31, 2018
The Role of Next-Generation Sequencing in Pharmacogenetics and PharmacogenomicsUte I Schwarz, Markus Gulilat, Richard B Kim
Digestive Diseases and Sciences|July 27, 2021
A Comparative Analysis of Drug Therapy, Disease Phenotype, and Health Care Outcomes for Men and Women with Inflammatory Bowel DiseaseEmily M Heath, Richard B Kim, Aze Wilson
Inflammatory Bowel Diseases|March 17, 2017
CYP3A4 Activity is Markedly Lower in Patients with Crohn's DiseaseAze Wilson, Rommel G Tirona, Richard B Kim
Cancer Chemotherapy and Pharmacology|November 11, 2022
Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotypeSamantha Medwid, Theodore J Wigle, Richard B Kim
Pageof 23